Paysign 2025 Q3 Earnings Record Net Income Surges 54.2%

Paysign (PAYS) reported fiscal 2025 Q3 earnings on Nov 14, 2025, with revenue rising 41.6% to $21.6 million, surpassing estimates of $19.92 million. The company raised full-year revenue guidance to $80.5–$81.5 million, reflecting 38.7% year-over-year growth. Net income hit $2.22 million, a 54.2% increase, while EPS climbed 33.3% to $0.04, exceeding expectations.

Revenue

Paysign’s revenue surged to $21.6 million in Q3 2025, driven by robust growth in its pharma patient affordability segment, which contributed $7.92 million—a 141.9% year-over-year increase. The plasma industry segment generated $12.86 million, reflecting 12.4% growth despite lower average revenue per center. Additional revenue streams, including other services, added $815,396 to the total.

Earnings/Net Income

Paysign’s profitability reached record levels, with net income climbing 54.2% to $2.22 million and EPS rising 33.3% to $0.04. These results underscore the company’s operational efficiency and strategic focus on high-margin segments. The 54.2% net income growth marks a 16-year high for Q3 earnings.

Post-Earnings Price Action Review

Following the earnings release, Paysign’s stock price declined 4.84% on the latest trading day, despite a 0.79% weekly gain. Over the month-to-date period, shares fell 9.72%, reflecting mixed investor sentiment. The drop contrasts with the company’s strong financial performance, potentially influenced by broader market dynamics or valuation concerns. Analysts remain optimistic, with a $9.00 average price target, but short-term volatility persists.

CEO Commentary

Mark Newcomer, President and CEO, highlighted record revenue of $21.6 million and a 78.1% increase in adjusted EBITDA to $5.04 million. He emphasized operational efficiencies and the expansion of patient affordability programs, which now number 105. Newcomer noted the opening of a 30,000-square-foot support center, quadrupling capacity, and expressed confidence in the plasma segment’s long-term potential despite current challenges.

Guidance

Paysign raised full-year 2025 revenue guidance to $80.5–$81.5 million, with plasma revenue expected to account for 57% of total revenue and pharma patient affordability programs contributing 41%. Net income is projected at $7.0–$8.0 million, or $0.12–$0.13 per diluted share, while Adjusted EBITDA is forecast at $19.0–$20.0 million. The company anticipates flat plasma revenue in Q4 and continued growth in pharma patient affordability programs.

Additional News

Paysign expanded its customer service infrastructure with a new 30,000-square-foot contact center, quadrupling support capacity to meet rising demand. The company also repurchased 100,000 shares of common stock during Q3, signaling confidence in its long-term value. Strategic initiatives include scaling plasma donor compensation solutions and enhancing its Software-as-a-Service platform. Institutional investors increased holdings, with Vanguard Group and Dimensional Fund Advisors boosting stakes by 1.6% and 47.9%, respectively, reflecting growing institutional confidence in the company’s growth trajectory.